Multi-Modality Imaging Standard Cohort Of Cerebrovascular Disease
ConditionCerebrovascular Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorBeijing Tiantan Hospital
About this trial
The aim of this study is to establish a multi-center and multi-modality imaging standard cohort of cerebrovascular disease, analyze the potential mechanisms affecting the prognosis of cerebrovascular disease based on a variety of imaging methods, and explore potential therapeutic targets.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age between 18 and 80 years old;
Onset of symptoms within 7 days;
Clinical diagnosis of cerebrovascular disease (ischemic stroke or hemorrhagic stroke) confirmed by head imaging (CT or MRI);
Signed informed consent form.
Disqualifiers
Diagnosed with non-cerebrovascular diseases (such as central nervous system infections, epilepsy, and metabolic encephalopathy);
Patients with contraindications to multimodal CT or MRI, functional near-infrared imaging, or those who cannot cooperate to complete the relevant examinations;
Patients with a life expectancy of less than 3 months or those who cannot complete the study follow-up due to other reasons.
Trial population
Patients aged 18-80 years old with acute cerebrovascular disease (hemorrhagic or ischemic stroke) within 7 days of onset； healthy adults.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
The incidence of unfavorable functional outcome
Unfavorable functional outcome is defined as mRS Score 2-5. mRS is an efficient, reliable and simple scale to assess the recovery of neurological function and disability after stroke. The high score indicates the poor neurological recovery. The minimum score (0) means no symptoms at all. The maximum (6) means death.
Time frame
3 month after enrollmentSecondary outcomes
1
The incidence of in-hospital complications
In-hospital complications (including stroke progression, recurrence, and mortality).
Time frame
duration of hospital stay（about 1 week）2
The incidence of unfavorable functional outcome
Unfavorable functional outcome is defined as the modified Rankin Scale (mRS) Score 2-5. mRS is an efficient, reliable and simple scale to assess the recovery of neurological function and disability after stroke. The high score indicates the poor neurological recovery. The minimum score (0) means no symptoms at all. The maximum (6) means death.
Time frame
6 and 12 months after enrollment3
The incidence of new vascular events
Including ischemic stroke, hemorrhagic stroke, myocardial infarction or vascular death.
Time frame
3, 6 and 12 months after enrollment4
The incidence of recurrent stroke
Stroke recurrence is defined as a new focal neurological impairment that was confirmed by neuroimaging, including both ischemic stroke and hemorrhagic stroke.
Time frame
3, 6 and 12 months after enrollmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov